Does anyone know how VT / CVBT is going. Website not much help. No response from management. Keen for any feedback. 🫣

AST said to contact Jon Ross (VT Board Member) regarding the shares.

Well, I've now learned that all CVBT shares were removed from AST. I assume someone is keeping track of these at the company in the unlikely event anything ever happens here.

Yes, I have a price, and they are held at AST.

Please contact me at briankelley52@gmail.com to discuss further.

Do you have a price in mind you would like to sell them at? Are they held at AST?

Anyone interested in purchasing 75K shares?

My shares
The same happened to me when Grant Gordon lived in the Philippines. First, through GHL, he managed my investments very poorly during a period when everybody else's investment went up. Secondly, I invested $30 000 in CVBT and have heard nothing after that so I consider the money lost.

What’s happening?

Something is hapening....do not write off your shares.

I remember being told this was what all the Lean Fortune 500 companies were doing. I guess they have been so successful with the CN raise that they have moved offices again. I guess they just forgot to update their website again.

I was in Dallas earlier this week. It happens that the company I work for has an office in the same building as the address listed on the Venturis website. I figured I'd pop in and see If I could chat with anyone. It turns out that the suite/address shown is a work share office and neither Venturis or CVBT was listed among the companies that rent space there.

Tumbleweeds

Is it just me of do other people find it odd that both the bulls and bears have gone quiet on this company?

Very quiet in this room these days.

Seems to have gone under…….even Lisa Ward has left the building.

So what is happening with the worthless cvbt shares I still own?
It's now 2022 !

Is there any real time updates on this company? I’m not talking a rehash of April’s events in the courts, because that’s total zzzz.

Are they still seeking funding as per the press release or have they gone into liquidation?

I’m not getting any response back from the company itself.

Thx

2021: The Great Reveal

2021 was the year where everything the naysayers have been saying was proven true. In April 2021, Venturis Therapeutics' long time counsel, Dentons, withdrew from representing the company. Dentons claimed in a court filing that Venturis had no ability to pay the $200,000+ it was owed, had no revenues, and no assets of value.

Here is the court filing:

DECLARATION OF BARRY F. CANNADAY IN SUPPORT OF MOTION TO WITHDRAW

I, Barry F. Cannaday, declare as follows in support of this Motion to Withdraw as an Attorney for Venturis Therapeutics, Inc. (“Venturis”) in the matter styled Daniel C. Montano and Dr. John W. Jacobs vs. Venturis Therapeutics, Inc., Case No. 2:20-cv-01410-GMN-BNW originally filed in the United States District Court for the District of Nevada, but which was closed on January 21, 2021 (the “Previously Closed Case”):

1. I am an attorney duly licensed to practice before all Courts in the State of Texas and I was admitted to practice Pro Hac Vice in the Previously Closed Case on behalf of Venturis on August 18, 2020. I have been a partner in the law firm of Dentons US, LLP since 2009.

2. Venturis initially agreed to retain Barry F. Cannaday in connection with the arbitration that was filed by Venturis against Mr. Montano and Dr. Jacobs (“Counter-Claimants”) on July 19, 2018. Following the issuance of the Arbitrator’s Final Award in that Arbitration on July 20, 2020, Counter-Claimants filed an Application for Order Confirming Arbitration Award in this Court on July 29, 2020. Barry F. Cannaday agreed to continue to represent Venturis in connection with the proceedings in this Court relating to Counter-Claimants attempts to confirm the Arbitration Award. This Court confirmed the Arbitration Award on January 25, 2021 and this case was thereafter closed on January 25, 2021.

3. On April 8, 2021 counsel for Counter-Claimants provided Barry F. Cannaday with copies of post-judgment Interrogatories and Requests for Production,. However, Barry F. Cannaday has not agreed to represent Venturis in any connection with post-judgment collection matters. Mr. Cannaday considered his representation of Venturis in this matter completed when this case was closed on January 25, 2021.

4. Further, as of March 31, 2021, Venturis owed Mr. Cannaday’s law firm, Dentons US LLP (“Dentons”), unpaid fees in excess of $200,000 for representation in this Previously Closed Case and for representation in the underlying arbitration.

5. Barry F. Cannaday performed his obligations as counsel for Venturis in the Previously Closed Case and in the underlying Arbitration in a skillful and diligent manner. However, Venturis has been rendered incapable of paying Mr. Cannaday’s law firm in accordance with the terms of its agreement.

6. Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made.

7. Barry F. Cannaday and Venturis have maintained a good working relationship throughout these proceedings. As such, the present Motion to Withdraw is not the result of any differences between Barry F. Cannaday and the client, but instead is the result of the inability of Venturis to meet its financial obligations to Dentons.

8. Defendant’s address is: 10455 Markison Road, Dallas, Texas 75238 and Barry F. Cannaday certifies that Venturis will be served with a copy of this Motion to Withdraw.

9. I personally visited with Jon Ross, Secretary and a Member of the Board of Directors of Venturis on Thursday, April 8, 2021 and advised him of my intention to file this notice and motion. Mr. Ross stated that Venturis had no objection to this Motion to Withdraw. I declare under penalty of perjury of the laws of the State of Nevada that the foregoing is true and correct.

Executed this 12th day of April, 2021.
/s/ Barry F. Cannaday
Barry, F. Cannaday, Esq.
DENTONS US LLP
2000 McKinney Ave
Suite 1900
Dallas, Texas 75201
Telephone: (214) 259-1855
Facsimile: (214) 259-0910

For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165949650

Not exactly direct competition with Venturis/CVBT's FGF-1 but Phase 2 data published on angiogenesis with VEGF-A from AZ and Moderna produced in vivo using mRNA injected directly into the heart.

The therapy, AZD8601, encodes for vascular endothelial growth factor (VEGF-A), a protein that induces the growth of blood vessels, and in a phase 2a trial met its primary endpoints of safety and tolerability in patients with heart failure.

https://www.fiercebiotech.com/biotech/aha-astrazeneca-moderna-shine-early-light-mrna-potential-heart-failure?oly_enc_id=6899J3333067F8K

Does anyone know if Venturis Therapeutics' attorneys, Dentons, knew that Venturis is in default when they quit on Venturis? It's hard to imagine they were not aware of this, but who knows?

For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166194302

CVBT/VT is in default in the state of Delaware and Nevada. It is no longer a legitimate corporation by any definition. Any attempt to raise money for an illegitimate corporation is fraud and a crime.

If you are someone you know is being contacted to put money into this company please contact the State of Nevada and/or Delaware's Department of Corporations Enforcement Division.

That is the status of the raise.

Does anyone have any information on this raise? Has any funding been secured? Is there a deadline for the raise?

Maybe, maybe not, just my opinion.

Perhaps you did not understand, it is no longer speculation.

The Nevada Secretary of State officially lists that VT is in default.

The State of Delaware states that VT has yet to file their taxes.

This is official records, Venturis Therapeutics has died. Administrators like Grant Gordon who were trying to boost the stock in September despite the corporation officially being in default in March seem to be liable for fraud.

Venturis is now officially dead, the Nevada Secretary of State said it in March, the Federal Court said it in April, and the state of Delaware said it in May.

There is no more speculation. VT is dead.

This can be found on official state websites, the company has legitimately and officially gone into default. But you're right the company website is up.

The Website is up and well. Speculation of the companies future at this point is moot. Time will tell and the repetitious doomsday predictions are getting old.

Venturis Therapeutics’ Official Default

My email has been battered today with news I had never imagined. Somehow it always gets worse for us shareholders at CVBT/VT.

Venturis’ phone number, 972-681-9368, has been disconnected and is no longer in service.

The Nevada Secretary of State’s website shows that Venturis Therapeutics has a status of “in default” as a result of its failure to file its annual list on May 31, 2021.

According to the state of Delaware, Venturis Therapeutics is also delinquent in the state of Delaware for its failure to pay its taxes as of March 2021.

It looks like the CVBT/VT administration is attempting to boost the stock with meaningless press-releases and questionable financing operations while slowly shutting down the company as they did with their press-release in September 2021.

Are the company administrators liable for fraud after attempting to boost the stock price despite knowing that the company was officially in default, failed to pay its taxes, and has a disconnected phone service, making it impossible to contact the offices? Could Grant Gordon and other administrators have the corporate veil pierced as a result of this clearly fraudulent and misleading information, giving the façade of business activity despite the slow shutdown of company offices, phone numbers, and failing to pay company fees and taxes??

OH NOOO!! Is it the END of VT/CVBT AGAIN?? How many more times and how many more years will the failed former CEO and his minions claim it's the end? Hahaha...

Venturis Therapeutics' legal counsel spills the beans

THE END OF VENTURIS/CVBT: The court filing by Venturis's lawyer

This declaration by Venturis Therapeutics's own lawyer, Dentons (one of the largest law firms in the country) withdrawing from representation on April 12, 2021, spills the beans on how hopeless the situation is at Venturis Therapeutics (formerly Cardiovascular Biotherapeutics, or CVBT). Dentons declared to the court under oath that Venturis has no ability to pay the $200,000+ plus Dentons is owed, and stated under penalty of perjury that Venturis Therapuetics has no assets or income streams that could repay the debt owed to Dentons. Here is Dentons' declaration in its entirety:

DECLARATION OF BARRY F. CANNADAY IN SUPPORT OF MOTION TO WITHDRAW

I, Barry F. Cannaday, declare as follows in support of this Motion to Withdraw as an Attorney for Venturis Therapeutics, Inc. (“Venturis”) in the matter styled Daniel C. Montano and Dr. John W. Jacobs vs. Venturis Therapeutics, Inc., Case No. 2:20-cv-01410-GMN-BNW originally filed in the United States District Court for the District of Nevada, but which was closed on January 21, 2021 (the “Previously Closed Case”):

1. I am an attorney duly licensed to practice before all Courts in the State of Texas and I was admitted to practice Pro Hac Vice in the Previously Closed Case on behalf of Venturis on August 18, 2020. I have been a partner in the law firm of Dentons US, LLP since 2009.

2. Venturis initially agreed to retain Barry F. Cannaday in connection with the arbitration that was filed by Venturis against Mr. Montano and Dr. Jacobs (“Counter-Claimants”) on July 19, 2018. Following the issuance of the Arbitrator’s Final Award in that Arbitration on July 20, 2020, Counter-Claimants filed an Application for Order Confirming Arbitration Award in this Court on July 29, 2020. Barry F. Cannaday agreed to continue to represent Venturis in connection with the proceedings in this Court relating to Counter-Claimants attempts to confirm the Arbitration Award. This Court confirmed the Arbitration Award on January 25, 2021 and this case was thereafter closed on January 25, 2021.

3. On April 8, 2021 counsel for Counter-Claimants provided Barry F. Cannaday with copies of post-judgment Interrogatories and Requests for Production,. However, Barry F. Cannaday has not agreed to represent Venturis in any connection with post-judgment collection matters. Mr. Cannaday considered his representation of Venturis in this matter completed when this case was closed on January 25, 2021.

4. Further, as of March 31, 2021, Venturis owed Mr. Cannaday’s law firm, Dentons US LLP (“Dentons”), unpaid fees in excess of $200,000 for representation in this Previously Closed Case and for representation in the underlying arbitration.

5. Barry F. Cannaday performed his obligations as counsel for Venturis in the Previously Closed Case and in the underlying Arbitration in a skillful and diligent manner. However, Venturis has been rendered incapable of paying Mr. Cannaday’s law firm in accordance with the terms of its agreement.

6. Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made.

7. Barry F. Cannaday and Venturis have maintained a good working relationship throughout these proceedings. As such, the present Motion to Withdraw is not the result of any differences between Barry F. Cannaday and the client, but instead is the result of the inability of Venturis to meet its financial obligations to Dentons.

8. Defendant’s address is: 10455 Markison Road, Dallas, Texas 75238 and Barry F. Cannaday certifies that Venturis will be served with a copy of this Motion to Withdraw.

9. I personally visited with Jon Ross, Secretary and a Member of the Board of Directors of Venturis on Thursday, April 8, 2021 and advised him of my intention to file this notice and motion. Mr. Ross stated that Venturis had no objection to this Motion to Withdraw. I declare under penalty of perjury of the laws of the State of Nevada that the foregoing is true and correct.

Executed this 12th day of April, 2021.
/s/ Barry F. Cannaday
Barry, F. Cannaday, Esq.
DENTONS US LLP
2000 McKinney Ave
Suite 1900
Dallas, Texas 75201
Telephone: (214) 259-1855
Facsimile: (214) 259-0910

For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165949650

No as I recall Montano owes 1.7 mill in the lawsuit he lost the Venturis. Nothing but speculation and innuendos put forth. Have a glorious investment as I am sure Montano's IPO is close, buy it up!!!.

Guys. They are right. VT should have tried to get a deal with RMO like shittya. RMOnopoly money is way better. After all look at what the hundreds of millions of fake money have done to transform shittya into the biotech powerhouse it is. Do you think Dan would have won biotech entrepreneur of the century without having inked such a blockbuster door. To think...two unknown companies like RMO and Shittya could come together, pretend to make an investment of fake money and ....go nowhere.

I received a phone call from Grant Gordon a couple days ago and he gave me an update and emailed me a lot of information. He wouldn't call a regular shareholder like me if there wasn't a good reason. I want to publicly thank the Admin team for working so hard behind the scenes. Hopefully we will start up from where we were back in 2008, but this time with leadership that wants us all to make money. GLTA

CVBT/VT does not even have drug yet, that is a half-decade process (approximately 5 years), they have no medical experts whatsoever that are capable to make the drug. I am doubtful that we will ever start clinical trials again.

Absolutely, CVBT/VT has epitomized what it means to progress as a biotech company. To celebrate the administration's seven-success since 2014, I have compiled a list highlighting some of their greatest achievements:

1. Lose every lawsuit to the former administration

2. Owe $1,000,000 to the former administration in a non-offsettable-judgement by the US Federal Court

3. Lose their legal representation because they had an inability to pay $200,000 in legal fees.

4. Have federal court records say that the company is completely valueless, has no revenue streams and no assets.

5. Has yet to make any progress what so ever in clinical trials.

6. Has yet to produce the drug they need for clinical trials

7. Has somehow downgraded their office space

8. Has signed a deal with a nobody company to secure the last $1 million dollars of the $100 million (if not more) that they need to raise.

9. Have their entire administration accused of fraud.

10. Have the CEO accused of embezzling money by the US Government

11. Have a known alcoholic run the PR at this forum.

12. File worthless patents

13. Attempting to sell highly-questionable convertible notes to innocent investors

Since this company is clearly moving in the right direction (if that direction is liquidation and bankruptcy), then why must our administration make fake news and try to argue that the stock is worth anything more than $0.01 per share, if that.

CVBT/VT is over. Expect another press release on this forum in another 6 months, maybe then they can raise a few pennies!

yes that is true all this wasted time and resources fighting off these idiots.

They (Mgt) had to stay quiet not to show their cards.

If this was such a lost cause they (Current Mgt) would have moved on long ago and same with Dan (who is forever bitter for blowing it).

Now its time for CVBT / Venturis to start moving again with trials.

Why would Venturis Therapeutic's leadership want any of us to discuss the unchallengable fact that Dentons, the company's long-time counsel, quit in April and stated under penalty of perjury to a court that Venturis has no assets of value nor income streams from which to pay $200,000+ in overdue invoices?

This very uncomfortable fact (which can not be challenged) completely invalidates and negates the narrative that Venturis Therapeutic's leadership continues to try to spin. Namely, that Venturis Therapeutics remains viable.

So I completely understand why Venturis Therapeutics' leadership would want us all to move beyond discussing that fact.

For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157492465

We have heard about the legal council dismissal 100 times. IN MY OPINION....this is a step forward for Venturis. Montano and his minions sat on their thumbs for years basically turning the company into a nepotism paradise milking all the money they could.

The company has turned a new page and reflecting on the same old derogatory dribble is really a bore.

Actually, yes.

And here's why: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165936410

NEWS ANALYSIS: The Prevail "deal"

In my opinion, the Prevail InfoWorks / Prevail Partners "deal" does the opposite of what Venturis Therapeutics (formerly CVBT) actually believes. Cutting through the nonsense, it appears that Venturis is buying some sort of software from Prevail, with some vague promise of future investment of a 7-figure amount after X, Y, and Z happen first (when Venturis needs an 8-figure or 9-figure investment) and if Venturis can raise other money first. So basically, if Venturis needs say $30 million (and they certainly need much more than that), Prevail will contribute the last million. Wowie zowie!!!!! Isn't that exciting?

What's really funny is that just in April 2021, Venturis's longtime legal counsel, Dentons, quit representing Venturis because Dentons was owed over $200,000 and stated in a sworn statement to the court that Venturis had no assets or income from which to repay the monies owed. That certainly sounds encouraging.

How much would anyone like to bet that Prevail is providing this software largely on credit, or with primarily backloaded cash costs and very little cash upfront?

I believe this whole nonsense deal instead telegraphs how weak and desperate Venturis Therapeutics actually is. That's not news to anyone that's been paying attention. I believe no one is going to invest in an insolvent, illiquid company where the CEO and controlling shareholder has been more than once accused of fraud, and who was accused by the U.S. government of stealing $14 million from his previous company (and those charges were quietly settled--and we all know what that means because if Mr. Wallen had actually been exonerated, we would be hearing that loud and clear). With just a modicum of due diligence, I believe anyone can see that Venturis Therapeutics is radioactive. Especially since the former CEO, Dan Montano, has won a $1MM+ judgment against the company and is in the process of collecting it.

The law is coming, and I believe Venturis Therapeutics will be liquidated by year-end. If the rumors I'm hearing are true, Venturis is one court action away from this happening. The actual judgment has already been declared against Venturis and affirmed.

For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157492465

Your frustrations have been discussed here ad nauseum on this board for the past 5 years. If you want more information call the company, sign a NDA and voila, you will see what's been going on. Also, the recent VT/CVBT PR should have created more optimism than pessimism...unless you're aligned with the previous administration, then I understand.

Correct me if this is a wrong statement, but the last official company review/update was a January 2020.

I don’t know any venture company that goes 20 months without an official update. As you would know most seed/venture companies are doing at least 2 updates a year. The better ones often do quarterly.

When was the last AGM where I could voice any question in an open forum?

It’s pretty hard to do DD if they are holding it all back from minority shareholders.

I’d love to see some updated audited financials.

Fwiw, the clown show board previous to this board was no better.

My points above are why I’m frustrated with the current setup.

Zero communication? False. I've had plenty of communication with VT/CVBT. Do your own due diligence.

Worst Private Company you've ever been involved with? Who's fault is that

A Realist? False. More like a Pessimist. A realist would've realized the situation as it is and move on. Furthermore, anyone that has been following CVBT/VT for the past decade would know this news is good news.

Conditional nature of the deal? If you know anything about business then you would know business deals often include conditions, especially deals of this magnitude. Calling it "fluff" is a typical pessimistic point of view.

It would be interesting to hear when you bought in to CVBT/VT and if you were in favor of the ousting of the former failed CEO.

“Small bits of news” really is accurate statement for this company.

Zero communication for 18months, with no AGM, and no end of year update for 2020.

I can safely say this is the worst run private company I’ll ever been involved with.

I’d love to be upbeat, but I’m a realist. Oddly you don’t have a response to the “conditional” nature of the deal. It’s mainly fluff.

Fwiw, that monthly diatribe of nonsense about VT going bust isn’t any better. You’re both as bad as each other. Signing a 1 month least at a wework, hahahahaha.

I see you lot going at it for years on this thread, yet ur wondering about me at parties hahahaha

Anyway, I hope your right and I get a chance to exit ASAP.

Ive never said they are liquidating.

I didn’t realise their old offices were free. The reality is they probably should just be working from home if they are running this lean. I look at the pricing of their new offices, and it seems to be a downgrade, with pricing for a desk that cheap. Not that the pricing in the old car park office would have be expensive.

Re press releases, 7 figures is “conditional”, so all they are doing is pumping their software(I assume they will charge VT). For a fund to invest a number that low on a conditional basis it’s not exactly a home run. They are clearly saving “if” u can raise along side we will help with tech and some cash.

Better than zero info for the last 18m though, so it’s at least positive.

I’m just saying cool ur jets, u can brag when when there is a real announcement like IPO.

Did you not see the Press Release?? Apparently the "optics" were good enough to secure a 7 figure deal with Prevail.

"That’s my point, and if u don’t get it your not a person in business"

Best quote of the year! Sounds like a Dan Montano USC (un)educated business (criminal)mind. Spend lavishly, try to steal money and BK CVBT because it's all about the optics! LOLLOLOLLOL

No I’m an owner of a decent clip, but spouting their current offices as a talking point isn’t a strong argument.

Name me any 900mio val company(320mio share at say 3.00) working from a wework.

Moving from some budget car park office to a wework in downtown isn’t an upgrade and remains extremely scuffly.

That’s my point, and if u don’t get it your not a person in business.

A company trying to raise millions in funding for trials probably shouldn’t be in a wework. Optics. Perhaps, focus on a stronger argument like patents owned etc.

Ha, you know that’s like a wework single desk right? Hardly highflying head offices to brag about.

I saw they have some newly leased office space in downtown Dallas as well. Must also be part of the "liquidation plan".

Bahahahaha

Does This Sound Like Venturis Therapeutics Is Liquidating? LOL

Venturis Therapeutics, Inc. Announces Strategic Alliance with Prevail
InfoWorks, Inc. and Prevail Partners, LLC
Dallas, TX - Venturis Therapeutics, Inc. (“VT” or the “Company”) announced it has entered into a strategic alliance with
Prevail InfoWorks, Inc. (“InfoWorks”), with the intent to deploy InfoWorks’ cutting-edge capabilities and technology to take
a leadership position in the management and the advancement of the VT Coronary Artery Disease trials. Further, VT
announces that to support the funding of initial trial, Prevail Partners, LLC, an affiliate of InfoWorks, has agreed in principle
to invest a seven figure amount in VT upon the commencement of the trial initiation activities.
VT expects that this relationship with InfoWorks, as assisted by the commitment of Prevail Partners, LLC, will allow VT to
expedite, enhance and refine the progression of its Coronary Artery Disease trials, as VT works to ultimately achieve FDA
approval for this indication. Further, VT, InfoWorks and Prevail Partners, LLC all anticipate that this relationship can be
mutually beneficial in the efforts of VT to advance other indications in VT’s biotechnology pipeline.
ABOUT VENTURIS THERAPEUTICS
Venturis Therapeutics, Inc. is a biopharmaceutical company developing protein drug candidates to address diseases such as severe coronary heart
disease, diabetic wounds, peripheral artery disease, erectile dysfunction, stroke, and spinal disk disease. The active pharmaceutical ingredient (“API”) in
our drug candidates is FGF-1, a human protein that stimulates the growth of new blood vessels, thereby increasing the blood supply to ischemic organs
and tissues.
ABOUT PREVAIL PARTNERS, LLC
Prevail Partners (www.prevailpartners.com) is an investment fund focused on life sciences companies. The fund is designed to take advantage of the
attractive returns possible in promising scientific advances in the life science fields of therapeutics, preventive treatments, medical devices and diagnostics.
A uniquely favorable feature of the fund is that Prevail InfoWorks applies proprietary technologies and services to equip companies in which the fund
invests, giving investors and strategic licensing partners the comfort that the clinical trials have a higher likelihood of success.
ABOUT PREVAIL INFOWORKS, INC.
For over a decade, Prevail InfoWorks (www.prevailinfoworks.com) has been dedicated to providing biotech, pharmaceutical, medical device and
diagnostics companies with the most innovative and complete technology and service solutions for the their clinical development. The company delivers
unique products and services that accelerate and de-risk drug development and clinical regulatory process more rapidly and cost effectively, including
through real-time actionable intelligence of evolving topline trends and metrics to patient specific data derived from aggregating all clinical, diagnostic,
operational and project accounting data. Prevail InfoWorks is an affiliate of Prevail Partners LLC.
FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those
discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are
forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of VT drug candidates, market
acceptance of VT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage, and financial
performance. Additionally, until VT is cash flow positive from operations, the Company is dependent upon raising capital to fund its operations and meet
its obligations as they come due. There can be no assurance that VT will be able to raise the necessary capital when needed.

ANOTHER LAUGHABLE HUUUGE YAAAAWN - LIQUIDATED AGAIN? AFTER 5 YEARS IS THIS REALLY THE END AGAIN FOR CVBT??

By the way, how did the fake awards ceremony go? I heard it was a real tear jerker for all the fake winners LOLOLOLOL